Controversial biotech CEO Martin Shkreli just lost money on his 'bad idea' Valeant bet
Bloomberg TV screenshot
"Exited the Allergan/Valeant trade. 3% loss or so. Bad idea. Onward and upward," Shkreli Tweeted on Monday.
Last Wednesday, Valeant's stock tanked after short-selling-firm Citron Research published a report asking if it was operating an Enron-like fraud.
That same day, Shkreli posted on Twitter that he was long Valeant and short Allergan.
"I have taken a long position in [Valeant] and shorted [Allergan] as a hedge. Both companies have similar prospects and one is at half the price," Shkreli Tweeted.
Valeant has said that they "categorically deny the allegations made in the Citron Report."
The company hosted an all-hands call on Monday morning to address the allegations. The stock was last trading down 3.3% at around $112.27 per share.
The stock is down about 23% since the Citron report came out.
Meanwhile, Allergan's stock has risen about 2.7% since last Wednesday.
Shkreli is the founder of Turing Pharmaceuticals, a biotech startup. He quickly became a household name last month after his company purchased the rights to a 62-year-old antiparasitic drug and then jacked up the price by more than 5,000%.
Valeant has also been criticized for its drug pricing. The company has also been compared to Shkreli.
In late September, Democrats on the House Oversight and Government Reform Committee sent a letter to the committee's chairman, Jason Chaffetz (R-UT), asking him to subpoena Valeant for documents related to price increases of acquired drugs.
The letter said that Valeant "is using precisely the same business model as Martin Shkreli, the 32-year-old former hedge fund manager whose company recently purchased the life-saving drug Daraprim and increased the price from $13.50 to $750 per pill 'overnight.'"
Exited the $AGN $VRX trade. 3% loss or so. Bad idea. Onward and upward.
- I'm an interior designer. Here are 10 things in your living room you should get rid of.
- A software engineer shares the résumé he's used since college that got him a $500,000 job at Meta — plus offers at TikTok and LinkedIn
- Higher-paid employees looking for work are having a tough time, and it could be a sign of a shift in the workplace
- Top tourist places to visit in Ooty in 2024
- Renewable energy accounted for 71 per cent of India's new power generation in FY 24
- ICC issues annual team rankings: India lead both white-ball formats while Aussies take top spot in Tests
- Bajaj Pulsar NS400Z launched at ₹1.85 lakh, becomes cheapest 400cc bike in the country
- 10 must-do activities on your next trip to Ooty in 2024
- Nothing Phone (2a) blue edition launched
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market